

Clinical Trial Results

Clinical Trial Protocol Number	27919
Title	A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.
Trial Phase	III
EudraCT Number	2007-002964-90
Sponsor	Newron Pharmaceuticals SpA, Italy
Organisation Posting Results	Affiliates of Merck KGaA, Darmstadt, Germany
Study Results	<p>The results of the study are available in the following publication:</p> <p>Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. <i>JAMA Neurol.</i> 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.</p>

Merck KGaA

These results are supplied for information purposes only.